Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03868904 · ClinicalTrials.gov registry record

INSPIRE Continuation Post-Approval Study

A clinical trial of Bronchiolitis Obliterans, sponsored by TransMedics.

Completed
Registry status
220
Enrollment target
17
Study locations

NCT03868904 is a study of Bronchiolitis Obliterans that has completed, run by TransMedics. The registered enrollment target is 220 participants, below the 384-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (43% lower). The trial reports 17 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03868904, a study of Bronchiolitis Obliterans, has completed, sponsored by TransMedics.

COMPLETED
Registry status
220 participants
Enrollment target
17
Study locations

Study Summary

To evaluate long-term BOS-free survival outcomes of the OCS™ Lung INSPIRE Trial patients.

Conditions Studied

Interventions

  • DEVICE OCS Lung System

Study Locations (17)

Other

  • University of Leuven Hospital - Leuven
  • N.H.C Hospital Civil - Strasbourg
  • German Heart Institute Berlin - Berlin
  • Hannover Medical School - Hanover
  • University of Padua - Padua
  • Hospital Universitario Puerta De Hierro - Madrid
  • Papworth Hospital - Cambridge
  • Harefield Hospital - Middlesex

California

  • UCLA Medical Center - Los Angeles
  • University of California at San Francisco - San Francisco

Arizona

  • St. Joseph's Hospital and Medical Center - Phoenix

Indiana

  • Indiana University - Indianapolis

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • University of Minnesota - Minneapolis

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

New South Wales

  • St. Vincent's Hospital - Darlinghurst

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2019-06-30
Est. Completion 2021-10-12

Sponsor

TransMedics

23 total trials

What the Registry Record Tells You About NCT03868904

The ClinicalTrials.gov registry entry for NCT03868904 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 384-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (43% lower). The listed sponsor is TransMedics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bronchiolitis Obliterans appearing as the primary indexed condition, and to 1 intervention - of which OCS Lung System is the first listed.

NCT03868904 reports 17 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT03868904 about?

NCT03868904 is a clinical study titled "INSPIRE Continuation Post-Approval Study". To evaluate long-term BOS-free survival outcomes of the OCS™ Lung INSPIRE Trial patients.

What is the current status of trial NCT03868904?

This trial is currently completed. The enrollment target is 220 participants. The study started on 2019-06-30. Estimated completion is 2021-10-12.

What conditions does trial NCT03868904 study?

This clinical trial studies the following conditions: Bronchiolitis Obliterans.

What interventions are being tested in trial NCT03868904?

The interventions under investigation include: OCS Lung System (DEVICE).

Who is sponsoring clinical trial NCT03868904?

This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03868904 being conducted?

This trial has 17 study locations across Arizona, California, Indiana, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bronchiolitis Obliterans

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.